10-Q · February 5, 2026
Prestige Consumer Healthcare Inc. reported mixed results for Q3 2026, with revenues declining 2.4% to $283.4 million compared to Q3 2025, while diluted EPS was slightly below estimates at $1.14. Despite ongoing…
Earnings analysis · 10-K
PBH earnings analysis
Filed May 14, 2026 · Our reading of the company's report
The latest report
Prestige Consumer Healthcare Inc. reported total revenues of $1.088 billion for fiscal 2026, a decline of 4.3% compared to the previous year, driven primarily by drops in the Eye & Ear Care segment. Gross profit margins…
Read full summary
Prestige Consumer Healthcare Inc. reported total revenues of $1.088 billion for fiscal 2026, a decline of 4.3% compared to the previous year, driven primarily by drops in the Eye & Ear Care segment. Gross profit margins decreased to 54.7%, influenced by rising costs and supply chain challenges. The firm has focused on acquisitions, expanding its product portfolio, including the recent purchase of Pillar5. Notably, the company recorded a $10.3 million write-off related to a supplier loan during the year, indicating ongoing financial pressures.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
From revenue to operating profit
Where each $100 of revenue went in this report.
Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $3.91
- Segment
- North American OTC Healthcare
- Segment
- International OTC Healthcare
What stood out
-
Total Revenue Decline
Revenues decreased by $49.1 million, or 4.3%, to $1.088 billion for fiscal 2026.
-
Gross Profit Margin Decline
Gross profit margin fell to 54.7% from 55.8%, indicating reduced profitability.
-
Free Cash Flow Generation
Free cash flow for 2026 was $257.6 million, an increase of $6.1 million from the previous year.
-
Acquisition Strategy
Acquired Pillar5 for $52.8 million, enhancing product offerings in the eye care segment.
-
Cost Management Efforts
Management is actively pursuing cost management strategies due to inflation and supply chain issues.
-
Share Buyback Program
Total share repurchased in fiscal 2026 was $162 million, reflecting commitment to returning value to shareholders.
What to watch
-
Supplier Loan Write-off
Wrote off $10.3 million related to a supplier loan, signaling financial distress in supply chain.
-
Dependency on Key Retailers
Walmart and Amazon collectively accounted for approximately 35% of revenues, heightening revenue risk if lost.
-
Supply Chain Disruptions
Continued supply chain challenges, especially in eye care products, expected to impact sales and customer relationships.
Management's outlook
No explicit numeric guidance provided; annual outlook deferred to earnings press release/call.
Earlier filings 4
10-Q · November 6, 2025
PBH reported Q2 2025 results with revenues of $274.1 million, down 3.4% from the prior year, and EPS of $1.07, exceeding estimates by 9.2%. The North American OTC Healthcare segment experienced a notable decline due to…
10-Q · August 7, 2025
Prestige Consumer Healthcare Inc. reported lower revenues of $249.5 million for Q1 2026, down 6.6% from Q1 2025, with diluted EPS of $0.95, missing estimates by $0.05. Despite challenges in the North American OTC…
10-K · May 9, 2025
Prestige Consumer Healthcare reported a modest revenue increase of $12.4 million to $1.138 billion for fiscal 2025, with net income climbing to $214.6 million. The company faced challenges in product supply and…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.